This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Seagen's (SGEN) Q1 Earnings and Revenues Miss Expectations
by Zacks Equity Research
Seagen (SGEN) reports worse-than-expected results in the first quarter of 2023, missing both earnings and sales estimates.
Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt Sales
by Zacks Equity Research
Bristol-Myers' (BMY) first-quarter 2023 earnings top estimates, while sales missed the same and declined year over year due to generic erosion for the oncology drug Revlimid.
Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 4.48% and 4.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $39.91, marking a -0.75% move from the previous day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Here's Why You Should Add Allogene (ALLO) Stock to Your Portfolio
by Zacks Equity Research
Allogene Therapeutics (ALLO), a top-ranked stock, is currently focused on developing allogenic CAR T therapies for treating cancer.
The Zacks Analyst Blog Highlights Pfizer, Accenture, Wells Fargo, Starbucks and Chubb
by Zacks Equity Research
Pfizer, Accenture, Wells Fargo, Starbucks and Chubb are part of the Zacks top Analyst Blog.
FDA Gives Nod for Using Bivalent Jab for All COVID Vaccinations
by Sundeep Ganoria
To simplify the COVID-19 vaccination schedule for all individuals, the FDA authorizes using bivalent COVID-19 vaccines for all doses administered to individuals aged six years and older.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $40.55, moving -1.53% from the previous trading session.
Finance Sector Scorecard and Analyst Reports for Pfizer, Accenture & Wells Fargo
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Accenture plc (ACN) and Wells Fargo & Company (WFC).
Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data
by Zacks Equity Research
Vaxcyte (PCVX) announces positive results from the mid-stage study of its 24-Valent pneumococcal conjugate vaccine candidate, VAX-24, in adults aged 65 and older.
FDA Expands AbbVie's (ABBV) Qulipta Label in Chronic Migraine
by Zacks Equity Research
Following FDA's label-expansion approval, AbbVie's (ABBV) Qulipta is the first and the only oral CGRP receptor antagonist approved to prevent episodic and chronic migraines.
Why Pfizer (PFE) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson (JNJ) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 6.77% and 5.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer (PFE) Stock Moves 0.14%: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $41.79, moving +0.14% from the previous trading session.
AstraZeneca (AZN), Sanofi Simply RSV Antibody Agreement Terms
by Zacks Equity Research
AstraZeneca (AZN) and Sanofi (SNY) revise the contractual terms of the agreement for Beyfortus. Sanofi will have full commercial control of Beyfortus in the United States.
3 Sector ETFs to Play as Recession Fears Are on the Rise
by Yashwardhan Jain
With recession fears on the rise, look into some sectors that can shield from market volatility.
The Zacks Analyst Blog Highlights J&J, AstraZeneca, Merck, Seagen and Pfizer
by Zacks Equity Research
J&J, AstraZeneca, Merck, Seagen and Pfizer are part of the Zacks Top Analyst Blog.
Zacks Investment Ideas feature highlights: Nvidia, United Healthcare, Merck, Pfizer and Intuitive Surgical
by Zacks Equity Research
Nvidia, United Healthcare, Merck, Pfizer and Intuitive Surgical are part of the Zacks Investment Ideas article.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Pharma Stock Roundup: J&J's $8.9B Offer for Talc Litigation Settlement & Other Updates
by Kinjel Shah
J&J (JNJ) offers a $8.9 billion settlement to resolve its talc lawsuits. FDA approves Merck's (MRK) Keytruda plus Seagen's Padcev for a bladder cancer indication.
3 Reasons to Buy Healthcare Stocks in the Current Market Environment
by Andrew Rocco
Healthcare stocks are currently providing investors with an attractive way to counterbalance a portfolio overexposed to tech. In general, healthcare stocks have lower betas, are more defensive, and have cleaner balance sheets.